MREO
MaterialsMereo Biopharma Group Plc
$0.24-0.04 (-14.89%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MREO Today?
No stock-specific AI insight has been generated for MREO yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$38M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding159.6M
MREO News
25 articles- European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday TradingYahoo Finance·May 6, 2026
- European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingYahoo Finance·May 5, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingYahoo Finance·Apr 30, 2026
- European Equities Traded in the US as American Depositary Receipts Lower in Wednesday TradingYahoo Finance·Apr 29, 2026
- European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday TradingYahoo Finance·Apr 21, 2026
- European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday TradingYahoo Finance·Apr 15, 2026
- European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday TradingYahoo Finance·Apr 13, 2026
- We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash WiselyYahoo Finance·Apr 7, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Monday TradingYahoo Finance·Apr 6, 2026
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOGlobeNewswire Inc.·Apr 3, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 3, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingYahoo Finance·Apr 2, 2026
- European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday TradingYahoo Finance·Apr 1, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREOGlobeNewswire Inc.·Mar 31, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 24, 2026
- European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for WeekYahoo Finance·Mar 20, 2026
- Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate HighlightsYahoo Finance·Mar 19, 2026
- European Equities Traded in US as ADRs Fall in Wednesday TradingYahoo Finance·Mar 18, 2026
- European Equities Traded in the US as American Depositary Receipts Higher TuesdayYahoo Finance·Mar 17, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Friday TradingYahoo Finance·Mar 13, 2026
- European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Down 5% for WeekYahoo Finance·Mar 6, 2026
- European Equities Traded in the US as American Depositary Receipts Tumble in Monday TradingYahoo Finance·Mar 2, 2026
- European Equities Traded in the US as American Depositary Receipts Little Changed in Friday TradingYahoo Finance·Feb 27, 2026
- European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday TradingYahoo Finance·Feb 26, 2026
All 25 articles loaded
Price Data
Open$0.28
Previous Close$0.28
Day High$0.29
Day Low$0.24
52 Week High—
52 Week Low—
Fundamentals
Market Cap$38M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding159.6M
About Mereo Biopharma Group Plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—